 CAMBRIDGE, Mass., June 04, 2021 GLOBE NEWSWIRE -- Surface Oncology Nasdaq: SURF, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced a clinical trial collaboration with Roche to evaluate SRF388, Surfaces investigational anti-IL-27 antibody, in combination with Roches atezolizumab and bevacizumab in patients with treatment-naïve hepatocellular carcinoma HCC. 